Business
InvestmentPitch Media Video Discusses Voyageur Pharmaceuticals' New "From the Earth to the Bottle" Fully-Integrated Iodine Business Strategy - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - February 27, 2020) - Voyageur Pharmaceuticals (...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"InvestmentPitch Media Video Discusses Voyageur Pharmaceuticals' New \"From the Earth to the Bottle\" Fully-Integrated Iodine Business Strategy - Video Available on Investmentpitch.comVancouver, British Columbia--(Newsfile Corp. - February 27, 2020) - Voyageur Pharmaceuticals (TSXV: VM) (OTCBB: VYYRF) announced its fully-integrated iodine business strategy which complements its ongoing barium contrast marketing strategy. Iodine contrast, a clear, water-based liquid sold in vials ranging from 15 milliliters to 500 milliliters, is one of highest volume consumables in healthcare.For more information, please view the InvestmentPitch Media \"video\" which provides additional information about this news and the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter \"Voyageur\" in the search box.Cannot view this video? Visit:http://www.investmentpitch.com/video/0_ui4xf8f6/Voyageur-Pharmaceuticals-announces-its-From-the-Earth-to-the-Bottle-Iodine-Contrast-strategyWater soluble, iodinated contrast media contains iodine atoms used for x-ray-based imaging such as computed tomography (CT), fluoroscopy, angiography and venography. Contrast agents can be subdivided into 3 groups which include Barium contrast media, Iodine contrast media and Gadolinium contrast media. Iodine contrast, the highest consumed contrast of the three groups, has a USA market estimated at $1.5 billion annually. Voyageur's Earth to the Bottle Iodine strategy will be completed in various stages.Stage 1 will start with drug registrations with the FDA and Health Canada. Stage 2 will see the company importing iopamidol and begin pharmaceutical manufacturing of the iodine contrast. Stage 3 will see the construction of an API (Active Pharmaceutical Ingredients) iopamidol plant where the company purchases iodine feedstock and produces its own active pharmaceutical ingredients. Stage 4 will see the production of iodine from subterranean brines with iodine concentrate feeding the API iopamidol plant.Upon completion of steps 1 to 4, Voyageur will achieve full integration for iodine contrast sales, allowing the company to be highly competitive by controlling all input costs under the motto of: \"From the Earth to the Bottle\". Brent Willis, CEO, stated: \"Voyageur will have a unique advantage as being the only company with direct ownership ...